Difference between revisions of "EU-METAHEART"
From Bioblast
| Line 40: | Line 40: | ||
Funded by the European Union. | Funded by the European Union. | ||
[[File:Flag yellow low.jpg|left|100px]] | [[File:Flag yellow low.jpg|left|100px]] | ||
<br/> | |||
<br/> | |||
Revision as of 14:22, 19 September 2023
EU-METAHEART
CA22169 - EUropean network to tackle METAbolic alterations in HEART failure (EU-METAHEART)
CA22169 - EUropean network to tackle METAbolic alterations in HEART failure (EU-METAHEART)
- MoU: 079/23
- CSO Approval date: 2023-05-12
- Duration: 48 months
- Start: 2023-10-18
About EU-METAHEART
Aims
- The COST Action “EUropean network to tackle METAbolic alterations in HEART failure” (EU-METAHEART) will bring together excellent researchers from Europe to contribute a broad spectrum of scientific expertise, cutting-edge technologies, scientific exchange and education to foster breakthrough science that moves the field forward towards improving the treatment of patients with heart failure. By sharing diverse expertise that cover not only conventional analyses of metabolism and mitochondrial function, but also omics-based approaches towards genetics, epigenetics and metabolism and in particular, integrated assessment of excitation-contraction coupling with mitochondrial redox control and energetics, as well as advanced in vivo imaging technologies, the novelty of this COST Action is that it will allow to develop a comprehensive and cutting-edge approach towards deeper understanding of metabolic dysfunction in HF. We have identified four scientific key areas to which metabolic or mitochondrial dysfunction are central, which will be addressed by four working groups (WGs):
- 1) Impact of metabolic disorders on substrate and intermediary metabolism in cardiac myocytes
- 2) Metabolic aspects of vascular dysfunction
- 3) Immunometabolism: how metabolic alterations control inflammation and vice versa
- 4) Mechano-energetic uncoupling and mitochondrial redox alterations
- These research areas are tightly intertwined and can hardly be investigated in isolation (from each other). Therefore, EU-METAHEART will employ an integrative approach to bring all these research fields under one umbrella. The working groups focus on their respective four topics, but benefit from the expertise in the respective other WGs to overcome scientific and methodological boundaries and rapidly move the field forward towards drug development.
Coordinator
Network
Management Committee
- See the list of the Management Committee here.
Oroboros project involvement
- Dr. Erich Gnaiger is a member of the Management Committee of the CA22169 - EUropean network to tackle METAbolic alterations in HEART failure (EU-METAHEART).
Links
News and articles
Support
Funded by the European Union.
